Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation

References

• Dijkmans TF, van Hooijdonk LW, Fitzsimons CP, Vreugdenhil E. The doublecortin gene family and disorders of neuronal structure. Cent Nerv Syst Agents Med Chem. 2010;10(1):32–46.
   PubMedGoogle Scholar
• Gzil A, Szylberg Ł, Jaworski D, Dominiak J, Zarębska I, Grzanka D. The essential role of DCLK1 in pathogenesis, diagnostic procedures and prognostic stratification of colorectal cancer. Anticancer Res. 2019;39(6):2689–2697.
   PubMed Web of Science ®Google Scholar
• Kalantari E, Razmi M, Tajik F, Asadi-Lari M, Ghods R, Madjd Z. Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis. Cancer Cell Int. 2022;22(1):217.
   PubMed Web of Science ®Google Scholar
• Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, et al. Dcamkl-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a mir-200a-dependent mechanism. Cancer Res. 2011;71(6):2328–2338.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020;16(6):635–643.
   PubMed Web of Science ®Google Scholar
• Wu X, Qu D, Weygant N, Peng J, Houchen CW. Cancer stem cell marker DCLK1 correlates with tumorigenic immune infiltrates in the colon and gastric adenocarcinoma microenvironments. Cancers. 2020;12(2):274.
   PubMed Web of Science ®Google Scholar
• Deng H, Qianqian G, Ting J, Aimin Y. Mir-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 2018;106:1072–1081.
   PubMed Web of Science ®Google Scholar
• Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12(3):296–300.
   PubMed Web of Science ®Google Scholar
• Sarkar B, Dosch J, Simeone DM. Cancer stem cells: a new theory regarding a timeless disease. Chem Rev. 2009;109(7):3200–3208.
   PubMed Web of Science ®Google Scholar
• Khan IN, Al-Karim S, Bora RS, Chaudhary AG, Saini KS. Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov Today. 2015;20(10):1205–1216.
   PubMed Web of Science ®Google Scholar
• Park JH, Chung S, Matsuo Y, Nakamura Y. Development of small molecular compounds targeting cancer stem cells. Med Chem Commun. 2017;8(1):73–80.
   Google Scholar
• Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and cancer stem cell marker DCLK1: a new target to enhance anti-tumor immunity in the tumor microenvironment. Cancers. 2020;12(12):3801.
   PubMed Web of Science ®Google Scholar
• Chhetri D, Vengadassalapathy S, Venkadassalapathy S, Balachandran V, Umapathy VR, Veeraraghavan VP, Jayaraman S, Patil S, Iyaswamy A, Palaniyandi K, et al. Pleiotropic effects of DCLK1 in cancer and cancer stem cells. Front Mol Biosci. 2022;9:965730.
   PubMed Web of Science ®Google Scholar
• Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, et al. DCLK1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 2017;16(1):30.
   PubMed Web of Science ®Google Scholar
• Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int Journal of Cancer. 2018;143(5):1162–1175.
   PubMed Web of Science ®Google Scholar
• Weygant N, Qu D, May R, Tierney RM, Berry WL, Zhao L, Agarwal S, Chandrakesan P, Chinthalapally HR, Murphy NT, et al. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget. 2015;6(4):2193–2205.
   PubMedGoogle Scholar
• Carli ALE, Afshar-Sterle S, Rai A, Fang H, O'Keefe R, Tse J, Ferguson FM, Gray NS, Ernst M, Greening DW, et al. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics. 2021;21(13–14):e2000098.
   PubMed Web of Science ®Google Scholar
• Patel O, Dai W, Mentzel M, Griffin MD, Serindoux J, Gay Y, Fischer S, Sterle S, Kropp A, Burns CJ, et al. Biochemical and structural insights into doublecortin-like kinase domain 1. Structure. 2016;24(9):1550–1561.
   PubMed Web of Science ®Google Scholar
• Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, et al. Xmd8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014;351(1):151–161.
   PubMed Web of Science ®Google Scholar
• Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, et al. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol. 2011;7(4):203–205.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS. Discovery of a series of 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as selective pi3k-delta/gamma inhibitors. ACS Med Chem Lett. 2016;7(10):908–912.
   PubMed Web of Science ®Google Scholar
• Selva M, Tundo P, Perosa A. Reaction of functionalized anilines with dimethyl carbonate over nay faujasite. 3. Chemoselectivity toward mono-n-methylation. J Org Chem. 2003;68(19):7374–7378.
   PubMed Web of Science ®Google Scholar
• Xia X, Zhai Y, Cui H, Zhang H, Hayat K, Zhang X, Ho CT. Glycine, diglycine, and triglycine exhibit different reactivities in the formation and degradation of amadori compounds. J Agric Food Chem. 2022;70(47):14907–14918.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, et al. Synthesis and structure-activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. J Med Chem. 2020;63(14):7817–7826.
   PubMed Web of Science ®Google Scholar
• Patel O, Roy MJ, Kropp A, Hardy JM, Dai W, Lucet IS. Structural basis for small molecule targeting of doublecortin like kinase 1 with DCLK1-in-1. Commun Biol. 2021;4(1):1105.
   Web of Science ®Google Scholar
• Bekes M, Langley DR, Crews CM. Protac targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.
   PubMed Web of Science ®Google Scholar